Physician profile
Ashley E Davis
NPI 1558710699
$2,757.88
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,301 · 2022: $420 · 2024: $36.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $36.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $36.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,242.68 | 2021-2024 | |
| Abbott Laboratories | $460.52 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.27 | 2021-2022 | |
| Amgen INC. | $183.25 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $183.13 | 2021 | |
| Lilly USA, LLC | $121.39 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $100.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $63.84 | 2021 | |
| Collegium Pharmaceutical, INC. | $48.45 | 2021 | |
| Allergan, INC. | $17.40 | 2021 | |
| Horizon Therapeutics Plc | $16.97 | 2021 | |
| Virtus Pharmaceuticals LLC | $16.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.67 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2021 | |
| Endo Pharmaceuticals INC. | $14.26 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $11.92 | 2021 | |
| Pfizer INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.